DR-441 A transcriptomic-driven machine learning model to predict the efficacy of CDK4/6-inhibitors in metastatic hormone-receptors positive breast cancer
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-441 A transcriptomic-driven machine learning model to predict the efficacy of CDK4/6-inhibitors in metastatic hormone-receptors positive breast cancer
In metastatic hormone receptor-positive (HR+/HER2-) breast cancer (mBC), cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6-i) in combination with endocrine therapy …
DR-466 Verification of the presence of chimeric transfer RNAs in the cytosol of cancer patients
We have demonstrated that genes coding for transfer RNAs accumulate large amounts of somatic mutations in human tumors. Some of …
DR-463 HYDRA: Integrative Molecular Characterization of Pancreatic and Esophagogastric Cancer for Personalized Treatment Optimization
Esophagogastric and pancreatic cancers are among the deadliest cancers, characterized by poor prognoses and limited treatment efficacy. Despite intensive research, …
DR-457 NRF2 pathway activation in metastatic urothelial carcinoma
Patients with advanced bladder cancer have incredibly poor outcomes. Over half of patients die within 5 years, many of them …
DR-452 AI-Driven Tumor-Agnostic MSI-H Prediction and Immunotherapy Response Modeling
Microsatellite instability (MSI) is a key biomarker of sensitivity to immune checkpoint inhibitors (ICIs) across tumour types. Despite its clinical …
DR-458 Whole genome sequencing for the investigation of novel genomic biomarkers in cancer
Cancer is caused by stepwise changes in the DNA sequence of the cell genome. In recent years, many common oncogenic …
DR-446 Fungal Contribution in Metastatic Cancer and Multi-Drug Treatment
This project explores the impact of fungi on cancer progression and treatment response. By examining fungal data from WGS and …
DR-462 Defining a Pan-Cancer Heterochromatin Instability Signature
This project aims to define a computational framework to identify gene expression signatures that reflect heterochromatin instability across multiple cancer …
DR-338 Systematic discovery and characterization of cancer-specific expression patterns
Cancer is driven by genetic changes, and multiple genes that have oncogenic and tumor suppressive potential have been widely investigated. …
DR-449 SOSCLC-AECC: Advancing Precision Oncology in Small Cell Lung Cancer and Related Neuroendocrine Lung Cancers through Multi-OMICs Profiling
This project, as part of the SOSCLC-AECC Consortium, represents the largest initiative to date in Spain focused on understanding the …
DR-460- Identifying the mutational burden of tumor specific regulatory elements (REs) in breast cancer
Gene regulation is controlled by regulatory elements (REs) which are present in the non-coding regions of the genome. Accessibility of …
DR-455 Identifying novel targets for cancer treatment
We aim to identify novel targets for cancer treatment. (1) We will assess whether biomarkers for immunotherapy outcome in melanoma, …
Het feit dat het CPCT het samen met Hartwig Medical Foundation voor elkaar heeft gekregen om data, kennis en kunde van vrijwel alle Nederlandse ziekenhuizen te bundelen, is uniek en krijgt inmiddels ook internationale aandacht.